GeneDx Holdings Corp.
GeneDx Holdings Corp.
Your view on WGS
Overview
What the company does, where it operates, and who runs it.
About GeneDx Holdings Corp.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Katherine A. Stueland
- Headquarters
- North Tower, Stamford, CT, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Katherine A. Stueland
- Headquarters
- North Tower, Stamford, CT, US
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.
The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for GeneDx Holdings Corp., and the rating behind it. WGS last traded at $61.26; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for GeneDx Holdings Corp.. Starting points for GeneDx Holdings Corp.: EPS -$3.58, beta 1.97 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for GeneDx Holdings Corp.. GeneDx Holdings Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for GeneDx Holdings Corp.. Trailing twelve-month EPS for GeneDx Holdings Corp. stands at -$3.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for GeneDx Holdings Corp.. GeneDx Holdings Corp. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
GeneDx Holdings Corp. valued side by side against its closest peers. GeneDx Holdings Corp. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold GeneDx Holdings Corp., and how their positions are changing. At a $1.83B market value, institutional positions materially move GeneDx Holdings Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by GeneDx Holdings Corp. executives and directors. Shares of GeneDx Holdings Corp. have traded between $55.17 and $147.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming GeneDx Holdings Corp.. GeneDx Holdings Corp. is a $1.83B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming GeneDx Holdings Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for GeneDx Holdings Corp.. Coverage tracks GeneDx Holdings Corp. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.